In newborns, we could recently demonstrate that reduced mHLA-DR expression may reflect immunological immaturity in very early newborns [90] and a meta-analysis on GM-CSF therapy indicated increased survival rates in very-low pre-term infants (< 2000 g) and infants with neutropenia when treated with GM-CSF [91]. The gene discussed is CSF2; the disease is neutropenia.